期刊文献+

结核分枝杆菌抗原重组酿酒酵母免疫诱导小鼠特异性免疫应答

The Vaccination with Saccharomyces cerevisiae Recombined with Mycobacterium tuberculosis Antigens Induces Specific Immunoresponsesin Mice
原文传递
导出
摘要 近年来基于重组酿酒酵母全细胞的新型疫苗研究报道不断出现。以结核杆菌重要保护抗原ESAT6和Ag85B为对象,采用p HR酿酒酵母表达系统,构建了两种分别表达ESAT6-Ag85B(EA)和IFN-γ-ESAT6-Ag85B(IEA)融合抗原的重组酿酒酵母Yeast-EA和Yeast-IEA。重组酵母以皮下注射方式免疫小鼠后,小鼠产生高水平Ag85B特异性抗体,淋巴细胞分泌IFN-γ、IL-2等细胞因子,无IL-4产生,发生Th1型细胞免疫应答,其中Yeast-IEA效应更强,优于传统的BCG疫苗。实验证实重组酵母能够刺激树突状细胞的成熟分化。研究结果显示结核分枝杆菌抗原重组酿酒酵母全细胞疫苗具有发展成为新型抗结核疫苗的潜力。 Recently there were increasing reports about vaccines based on whole recombinant Saccharomyces cerevisiae. Mycobacterium tuberculosis (Mtb) protective antigens ESAT6 and Ag85B against tuberculosis were selected to be expressed in S. cerevisiae with pHR expression system. Two yeasts producing fusion proteins ESTA6-Ag85B (EA) and IFN-γ-ESAT6-Ag85B(IEA) respectively were constructed and the immune responses elicited by the recombinant yeasts were investigated in mice. Injection of mice subcutaneously with the recombinant yeasts induced Ag85B-specific IgG in high level and Thl immune responses associated with IFN-γ and IL-2 secretion and no IL-4 production. Compared to BCG, Yeast-IEA vaccination stimulated significantly stronger immune response. It was confirmed that yeast could activated dendritic cells maturation with upregulation of co-stimulatory molecules and MHC molecules. The results suggest that the whole recombinant yeast ( Yeast- IEA) may be an attractive candidate of vaccines against tuberculosis.
出处 《中国生物工程杂志》 CAS CSCD 北大核心 2014年第11期47-53,共7页 China Biotechnology
基金 "十二五"国家科技重大专项(2012ZX10003002-002) 上海市基础研究重点项目(08JC1401100)资助项目
关键词 酿酒酵母 疫苗 结核分枝杆菌 BCG Saccharomyces cerevisiae Vaccine Mycobacterium tuberculosis BCG
  • 相关文献

参考文献17

  • 1江佳稀,张宇飞,沈洪波,王洪海,刘建平.表达结核杆菌抗原的重组酿酒酵母免疫小鼠研究[J].复旦学报(自然科学版),2011,50(2):192-198. 被引量:2
  • 2Haller A A,Lauer G M,King T H,et al.Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins.Vaccine,2007,25(8):1452-1463.
  • 3Dietrich J,Doherty T M.Interaction of Mycobacterium tuberculosis with the host:consequences for vaccine development.APMIS,2009,117:440-457.
  • 4Celik E,Calik P.Production of recombinant proteins by yeast cells.Biotechnology Advances,2012,30:1108-1118.
  • 5Tsolaki A G,Nagy J,Leiva S,et al.Mycobacterium tuberculosis anresponse in a murine vaccination model.Molecular Immunology,2013,54(3-4):278-283.
  • 6Kaufmann S H.Fact and fiction in tuberculosis vaccine research:10 years later.Lancet Infect Dis,2011,11:633-640.
  • 7Sable S B,Verma I,Khuller G K,et al.Multicomponent antituberculous subunit vaccine based on immunodominant antigens of Mycobacterium tuberculosis.Vaccine,2005,23:4175-4184.
  • 8Lalvani A,Sridhar S,von Reyn C F.Tuberculosis vaccines:time to reset the paradigm.Thorax,2013,68(12):1092-1094.
  • 9Bernstein M B,Chakraborty M,Wansley E K,et al.Recombinant Saccharomyces cerevisiae(yeast-CEA)as a potent activator of murine dendritic cells.Vaccine,2008,26(4):509-521.
  • 10Sable S B,Verma I,Khuller G K,et al.Multicomponent antituberculous subunit vaccine based on immunodominant antigens of Mycobacterium tuberculosis.Vaccine,2005,23:4175-4184.

二级参考文献15

  • 1WHO. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings [EB/OL]. (2010-10-28)[2010-11-04]. http://www. who. int/tb/puhlications/2010/en/index, html.
  • 2Dietrich J, Doherty T M. Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development[J]. APMIS, 2009,117(5 6): 440-457.
  • 3Barker L F, Brennan M J, Rosenstein P K, et al. Tuberculosis vaccine research: the impact of immunology[J]. Current Opinion in Immunology , 2009,21(3) : 331-338.
  • 4Sable S B, Verma I, Khuller G K, et al. Multicomponent antituberculous subunil vaccine based on immunodominant antigens of Mycobacterium tuberculosis[J]. Vaccine, 2005,23(32) : 4175 -4184.
  • 5Coler R N, Dillon D C, Skeiky Y A, et al. Identification of Mycobacterium tuberculosis vaccine candidates using human CD4^+ T-cells expression cloning[J]. Vaccine, 2009,27(2): 223 -233.
  • 6Hoft D F. Tuberculosis vaccine development: goals, immunological-design, and evaluation[J]. Lancet, 2008,372(9633) : 164-175.
  • 7Stubhs A C, Martin K S, Coeshott C, et al. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell mediated immunity[J]. Nature Medicine, 2001,7(5): 625- 629.
  • 8Bernstein M B, Chakraborty M, Wansley E K, et al. Recombinant Saccharomyces cerevisiae (yeast CEA) as a potent activator of routine dendritic cells[J]. Vaccine, 2008,26(4): 509-521.
  • 9Hovav A H, Fishman Y, Bercovier H. Gamma interferon and monophosphoryl lipid A-trehalose dicornomycolate are efficient adjutants for Mycobacterium tuberculosis multivalent acellular vaccine[J]. Infection and Immunity, 2005,73(1) : 250-257.
  • 10Galao R P, Scheller N, Alves Rodrigues I, et al. Saccharomyces cerevisiae: a versatile eukaryotic system in virology[J]. Microbial Cell Factories, 2007,6: 32-32.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部